ProPhase Labs, Inc. Deferred Tax Assets, Operating Loss Carryforwards, Domestic
ProPhase Labs, Inc. (PRPH) had Deferred Tax Assets, Operating Loss Carryforwards, Domestic of $10.90 million as of 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic · last filed 2026-06-01
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $10.90M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $3.40M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $3.10M.
- 2016-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $47.10M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Domestic | Deferred Tax Assets, Operating Loss Carryforwards, Domestic as first filed |
|---|---|---|
| 2025-12-31 | $10.90M 10-K · filed 2026-06-01 | |
| 2024-12-31 | $3.40M 10-K · filed 2025-04-01 | |
| 2023-12-31 | $3.10M 10-K · filed 2024-03-29 | |
| 2016-12-31 | $47.10M 10-Q/A · filed 2018-08-20 | |
| 2015-12-31 | $47.10M 10-K · filed 2017-02-24 | $44.50M 10-K · filed 2016-03-29 |
| 2012-12-31 | $37.70M 10-Q · filed 2013-11-13 | |
| 2012-06-30 | $31.60M 10-Q · filed 2012-08-13 | |
| 2011-12-31 | $31.60M 10-Q · filed 2012-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |